26-06-2020
The executive director of the Medicines Patent Pool (MPP) says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
MPP, LSPN Connect, Medicines Patent Pool, voluntary licensing, COVID-19, pandemic, Charles Gore, Big Pharma, drug companies, HIV, hepatitis C, WHO, UN
LSPN Connect: micro-managing with Pendulum Therapeutics
06-08-2020
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31-07-2020
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23-07-2020
LSPN Connect: When IP and COVID-19 meet
10-07-2020
WHO and Costa Rica to launch COVID-19 technology patent pool
19-05-2020
Costa Rica asks WHO to create voluntary COVID-19 IP pool
26-03-2020
